预约演示
更新于：2025-11-22
Tropicamide
托吡卡胺
更新于：2025-11-22
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20N2O2 |
InChIKeyBGDKAVGWHJFAGW-UHFFFAOYSA-N |
CAS号1508-75-4 |
关联
27
项与 托吡卡胺 相关的临床试验CTRI/2025/04/085126
A clinical study to evaluate the efficacy and safety of Kakamachi (Solanum nigrum ) extract as a natural pupil dilator in comparison with conventional pharmaceutical agent- tropicacyl plus - NIL
CTRI/2024/08/072980
To evaluate changes in hemodynamic parameters in hypertensive and nomotensive patients using intracameral injection of a mix Tropicamide 0.2 percentage . Phenylnephrine 0.31 percentage . Lidocaine 10 mg in patients undergoing cataract surgerv An interventional study - NIL
TCTR20250312005
The comparative efficacy of a combination of 0.5% cyclopentolate tropicamide, and alternating instillation of 1% cyclopentolate and 1% tropicamide in Thai pediatric refraction
100 项与 托吡卡胺 相关的临床结果
登录后查看更多信息
100 项与 托吡卡胺 相关的转化医学
登录后查看更多信息
100 项与 托吡卡胺 相关的专利（医药）
登录后查看更多信息
1,186
项与 托吡卡胺 相关的文献（医药）2026-01-01Ophthalmology science
Assessing the Impact of Pharmacological Pupil Dilation on Anterior Chamber Cells Counting Using OCT
作者: Chisari, Domenico ; Invernizzi, Alessandro ; Oldani, Marta ; Zicarelli, Federico ; Manni, Priscilla ; Airaldi, Matteo ; Romano, Francesco ; Zaffalon, Chiara ; Barbieri, Lucrezia ; Cimino, Luca
Purpose:
Anterior chamber (AC) cells are seen as hyperreflective dots (HRDs) on anterior segment OCT (AS-OCT), but many factors can affect their objective counting. The aim of this study was to evaluate the effect of pharmacological dilation with tropicamide 0.5% (T) or phenylephrine 2.5% + tropicamide 0.5% (PH + T) on the assessment of AC HRDs density measured in healthy eyes by AS-OCT.
Design:
Cross-sectional, observational study.
Participants:
Healthy subjects with no history of uveitis, no ocular or systemic conditions, and no recent ocular surgery.
Methods:
Participants underwent comprehensive ophthalmic examinations, including single-line AS-OCT (16.5 mm; μm:pixel ratio = 8.79; Anterion, Heidelberg Engineering) imaging before (miosis) and after pupil dilation with either T or PH + T drops. Hyperreflective dots were quantified using FIJI (National Institutes of Health, Bethesda) through the Analyze Particles tool after image binarization. Hyperreflective dot density was calculated by dividing the total HRDs by the AC area and expressed as the number per 10 000 pixels². Iris displacement after dilation was measured using the apex-to-pupil distance (APD).
Main Outcome Measures:
Anterior chamber HRDs density before and after dilation measured by AS-OCT. A generalized Poisson mixed-effects model was used to evaluate the effects of group (miosis, T, PH + T), lens status (phakic, pseudophakic), and their interaction on HRD density. Covariates included age, sex, iris color, and variation in APD after dilation (APDD).
Results:
A total of 100 eyes from 59 healthy participants (55.9% female), mean age 73.0 ± 11.7 years were included. Mean (standard deviation) HRDs density (per 10 000 pixels²) significantly increased from 0.79 (1.44) in normal photopic conditions to 1.71 (3.30) after the dilatation in the T group and from 0.52 (0.83) to 15.8 (25.8) in the PH + T group (P < 0.001). Dilation with T (P = 0.03) or PH + T (P < 0.001), increased APDD (P < 0.001), and the interaction between PH + T and phakic status (P < 0.001) were all significantly associated with higher HRDs density.
Conclusions:
Pharmacological dilation, especially with PH + T, significantly increases HRDs in the AC of healthy subjects, with a more pronounced effect in phakic eyes and greater APDD. These findings suggest increased iris-lens friction and potential pigment release after dilation, providing critical considerations for standardizing AS-OCT-based assessments of AC inflammation.
Financial Disclosures:
The author has no/the authors have no proprietary or commercial interest in any materials discussed in this article.
2025-11-01ACTA OPHTHALMOLOGICA
Effect of anticholinergic eye drops on intraorbital, periorbital and brain pulsation power
Article
作者: Honkamo, Marja ; Huotari, Niko ; Kiviniemi, Vesa ; Ebrahimi, Seyed Mohsen ; Raitamaa, Lauri ; Tuunanen, Johanna ; Saarela, Ville ; Korhonen, Vesa ; Kananen, Janne
Abstract:
Purpose:
The study aims to investigate the effect of pharmacologically reducing parasympathetic activity on ocular and cerebral pulsations, inspired by recent discoveries of a glymphatic‐like system in the eye driven by physiological pulsations.
Methods:
Forty‐six healthy volunteers were subjected to fMREye imaging, with 23 receiving topical tropicamide and 23 serving as controls. Additionally, 83 healthy volunteers were scanned using 3D whole‐brain magnetic resonance encephalography (MREG). Ocular pulsation power across very low‐frequency, respiratory and cardiac bands was quantified in each individual.
Results:
Topical tropicamide significantly reduced physiological pulsation power throughout the eye, including the cornea, lens, vitreous body, retina and optic nerve. Similar reductions were observed in the untreated eye, indicating potential systemic effects. In the brain, significant pulsation changes were noted in the venous sinus and internal carotid artery following tropicamide application.
Conclusion:
The findings suggest parasympathetic activity is crucial in modulating physiological pulsations in both ocular and cerebral glymphatic pathways. This interplay may have implications for conditions involving impaired fluid dynamics, such as glaucoma and traumatic brain injury.
2025-10-01Photodiagnosis and Photodynamic Therapy
Optical fogging is an effective method of reducing overestimation of myopia
Article
作者: Yu, Yang ; Chen, Yinhe ; Huang, Luoming ; Chen, Ting ; Lin, Zequn ; Lin, Jiajia ; Xiong, Xinyao
BACKGROUND:
This study aimed to investigate the effectiveness of optical fogging in controlling accommodation and to evaluate its efficiency in reducing myopic overestimation among young adults, with the goal of providing scientific evidence for clinical refractive measurement.
METHODS:
A total of 142 young adults aged 17 to 23 years (284 eyes) were enrolled. Refractive status and ocular biometric parameters were measured using open-field autorefractor and partial coherence interferometry under three conditions: baseline, optical fogging, and cycloplegia. Optical fogging was induced by wearing +2.00 D spherical lenses for 20 min, while cycloplegia was induced using 0.5 % compound tropicamide-phenylephrine eye drops. Eyes were categorized into overestimated and non-overestimated myopia groups based on whether the difference in spherical equivalent (SE) between cycloplegic and baseline measurements was ≥0.50 D. Changes in SE and lens thickness under the three conditions were analyzed, and the efficiency of optical fogging-induced accommodative control was calculated.
RESULTS:
In the overestimated myopia group (82 eyes), optical fogging reduced accommodation by an average of 0.28 ± 0.37 D compared to baseline (p < 0.001), accounting for 36.84 % of the effect of cycloplegia (0.76 ± 0.29 D). In the total sample eyes, optical fogging reduced accommodation by 0.07 ± 0.34 D (p < 0.001), which corresponded to 21.88 % of the cycloplegic effect (0.32 ± 0.37 D). Lens thickness showed no significant change after optical fogging (all p > 0.05).
CONCLUSIONS:
Optical fogging effectively suppresses unnecessary accommodative responses in young adults, significantly reducing myopic overestimation, with particularly pronounced effects in those with notable myopic overestimation. Although optical fogging is less effective than cycloplegia in relaxing accommodation, it offers advantages in terms of ease of use, non-invasiveness, and good tolerance, making it highly applicable in clinical refractive measurement.
100 项与 托吡卡胺 相关的药物交易
登录后查看更多信息
研发状态
临床结果
临床结果
适应症
分期
评价
查看全部结果
EURETINA2024 人工标引  | N/A | - | 53 | 夢醖憲網襯繭獵襯獵鬱(獵餘築網壓襯憲範廠壓) = 糧淵構膚遞範觸築鑰願 膚簾築鑰壓鬱糧淵鏇艱 (製選窪餘鑰鏇淵艱艱廠 ) 更多 | 积极 | 2024-09-19 | |
临床4期 | 11 | 構鹹範窪觸鑰壓獵艱壓 = 遞製製夢選願醖壓範範 廠製觸壓範積憲鬱齋憲 (鏇襯廠願淵遞網簾醖淵, 憲積網簾獵夢膚襯鬱餘 ~ 鬱鹽廠繭鹹構製膚獵繭) 更多 | - | 2023-03-07 | |||
临床3期 | - | 鏇齋觸鏇遞觸餘夢願淵(顧繭鹹獵鑰糧網窪鏇網) = 製衊窪鹽鹹餘餘襯鹽獵 餘鬱廠夢廠範築蓋淵網 (窪淵網淵衊鬱遞餘壓窪 ) | 积极 | 2021-11-13 | |||
临床4期 | 38 | (DMEK) | 淵廠鹽糧顧顧鹽襯襯齋(糧壓壓糧夢衊醖醖窪窪) = 觸餘積齋積壓遞鏇顧憲 鹹鹽範憲糧製憲衊願淵 (廠選獵獵選艱壓憲廠繭, 0.11) 更多 | - | 2019-07-02 | ||
(DSAEK) | 範製憲網糧窪鬱積蓋簾(繭簾網網糧鏇鹹憲構築) = 製艱壓膚觸獵範醖蓋簾 範夢範鹽憲積衊夢繭鑰 (積築艱鏇鬱構襯鬱鏇觸, 0.136) 更多 | ||||||
临床2期 | 19 | 網觸憲範衊廠鹹觸鹹製(簾窪壓範繭淵顧齋廠繭) = 簾廠鑰鬱窪觸艱窪鑰衊 獵衊網蓋願觸壓衊衊鬱 (顧鑰淵夢醖夢衊蓋夢壓, 0.51) 更多 | - | 2015-10-12 | |||
临床2期 | 19 | 鬱構繭積衊構蓋淵繭衊(顧築鑰艱鬱夢夢簾齋衊) = 簾積蓋夢顧遞壓蓋糧鏇 築鹹淵願鑰廠積選淵糧 (獵願築窪觸構遞鏇觸鹽 ) | 积极 | 2011-11-15 | |||
鬱構繭積衊構蓋淵繭衊(顧築鑰艱鬱夢夢簾齋衊) = 製積膚襯積壓構簾窪窪 築鹹淵願鑰廠積選淵糧 (獵願築窪觸構遞鏇觸鹽 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用